Genetics and diabetic retinopathy

Current Diabetes Reviews

Volumn 9, Issue 1, 2013, Pages 86-92

  Schwartz, Stephen G ^a   Brantley, Milam A ^b   Flynn, Harry W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aldose reductase; Candidate gene; Diabetic retinopathy; Genome wide association study; Receptor for advanced glycation end products; Vascular endothelial growth factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOKINASE; HLA ANTIGEN; INSULIN RECEPTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN B; SOMATOMEDIN C; VASCULOTROPIN;

5' UNTRANSLATED REGION; ARTICLE; CHROMOSOME 1; CHROMOSOME 12; CHROMOSOME 3; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GLYCEMIC CONTROL; HERITABILITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INDEL MUTATION; INSULIN DEPENDENT DIABETES MELLITUS; LINKAGE ANALYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLIC REGULATION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR;

EID: 84875962220     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339913804143171     Document Type: Article

References (107)

1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105: 998-1003.
2. Hohman TC, Nishimura C, Robison WG Jr. Aldose reductase and polyol in cultured pericytes of human retinal capillaries. Exp Eye Res 1989; 48: 55-60.
3. Brownlee M. Banting lecture 2004: the pathobiology of diabetic complications, a unifying mechanism. Diabetes 2004; 54: 1615-1625.
4. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999; 48: 1899-1906.
5. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP. Diabetes retinopathy and angio genesis. Curr Diabetes Rev 2009; 5: 8-13.
6. Fong DS, Aiello LP, Ferris FL III, Klein R. Diabetic retinopathy. Diabetes Care 2004; 27: 2540-2553.
7. Klein R. The epidemiology of diabetic retinopathy: findings from the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Int Ophthalmol Clin 1987; 27: 230-238.
8. The Diabetes Control and Complications Trial Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
9. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
10. Rodriguez-Frontal M, Kerrison JB, Alfaro DV 3rd, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009; 5: 3-7.
11. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994; 101: 1061-1070.
12. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.
13. Zhang L, Chen B, Tan L. Metabolic memory: mechanisms and implications for diabetic retinopathy. Diabetes Res Clin Pract 2012; 96: 286-293.
14. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987; 36: 808-812.
15. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409-2417.
16. Madsen-Bouterse SA, Mohammad G, Kanwar M, Kowluru RA. Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression. Antioxid Redox Signal 2010; 13: 797-805.
17. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin 2009; 49: 35-52.
18. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006; 141: 446-455.
19. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A US population study. Diabetes Care 1998; 21: 1230-1235.
20. Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes 1988; 37: 878-884.
21. Leslie RD, Pyke DA. Diabetic retinopathy in identical twins. Diabetes 1982; 31: 19-21.
22. The Diabetes Control and Complications Trial Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 1829-1839.
23. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian type 2 diabetic patients. Diabet Med 2002; 19: 910-916.
24. Hallman DM, Huber JC Jr, Gonzalez VH, Klein BE, Klein R, Hanis CL. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care 2005; 28: 1163-1168.
25. Zhang X, Gao Y, Zhou Z, Wang J, Zhou Q, Li Q. Familial clustering of diabetic retinopathy in Chongqing, China, type 2 diabetic patients. Eur J Ophthalmol 2010; 20: 911-918.
26. Arar NH, Freedman BI, Adler SG, et al. Family Investigation of Nephropathy and Diabetes Research Group. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci 2008; 49: 3839-3845.
27. Hietala K, Forsblom C, Summanen P, Groop PH. Heritability of proliferative diabetic retinopathy. Diabetes 2008; 57: 2176-2180.
28. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
29. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure: a six-year followup study in Pima Indians. N Engl J Med 1980; 305: 645-650.
30. Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes 2006; 114: 275-294.
31. Bennett PH, Burch TA, Miller M. Diabetes mellitus in American (Pima) Indians. Lancet 1971; 2: 125-128.
32. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998; 47: 821-830.
33. Hallman DM, Boerwinkle E, Gonzalez VH, Klein BE, Klein R, Hanis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas. Diabetes 2007; 56: 1167-1173.
34. Looker HC, Nelson RG, Chew E, et al. Genome-wide linkage analyses to identify loci for diabetic retinopathy. Diabetes 2007; 56:1160-1166.
35. Al-Kateb H, Mirea L, Xie X, et al. DCCT/EDIC Research Group. Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes 2007; 56: 2161-2168.
36. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635-1639.
37. Suganthalakshmi B, Anand R, Kim R, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis 2006; 12: 336-341.
38. Szaflik JP, Wysocki T, Kowalski M, et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 39-43.
39. Awata T, Kurihara S, Takata N, et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005; 333: 679-685.
40. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant 2007; 22: 827-832.
41. Chun MY, Hwang HS, Cho HY, et al. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J Clin Endocrinol Metab 2010; 95: 3547-3551.
42. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 21-26.
43. Feghhi M, Nikzamir A, Esteghamati A, Mahmoudi T, Yekaninejad MS. Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Transl Res 2011; 158: 85-91.
44. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004; 53: 861-864.
45. Churchill AJ, Carter JG, Ramsden C, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci 2008; 49: 3611-3616.
46. Uthra S, Raman R, Mukesh BN, et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet 2008; 29: 11-15.
47. Wang Y, Ng MC, Lee SC, et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003; 26: 2410-2415.
48. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Length rather than a specific allele of dinucleotide repeat in the 5' upstream region ofthe aldose reductase gene is associated with diabetic retinopathy. Diabet Med 1999; 16: 1044-1047.
49. Ichikawa F, Yamada K, Ishiyama-Shigemoto S, Yuan X, Nonaka K. Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5'-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with type 2 diabetes mellitus. Diabet Med 1999; 16: 744-748.
50. Ikegishi Y, Tawata M, Aida K, Onaya T. Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro. Life Sci 1999; 65: 2061-2070.
51. Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet 2003; 24: 41-48.
52. Uthra S, Raman R, Mukesh BN, et al. Diabetic retinopathy: validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south Indian cohort. Ophthalmic Genet 2010; 31: 244-251.
53. Olmos P, Futers S, Acosta AM, et al. (AC)23 Z-2. polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics. Diabetes Res Clin Pract 2000; 47: 169-176.
54. Richeti F, Noronha RM, Waetge RT, et al. Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol Vis 2007; 13: 740-745.
55. Li Q, Xie P, Huang J, Gu Y, Zeng W, Song H. Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus. Chin Med J (Engl) 2002; 115: 209-213.
56. Park HK, Ahn CW, Lee GT, et al. (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 151-157.
57. Santos KG, Tschiedel B, Schneider J, Souto K, Roisenberg I. Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract 2003; 61: 133-136.
58. Lindholm E, Bakhtadze E, Cilio C, Agardh E, Groop L, Agardh CD. Association between LTA, TNF and AGER polymorphisms and late diabetic complications. PLoS One 2008; 3: e2546.
59. Ramprasad S, Radha V, Mathias RA, Majumder PP, Rao MR, Rema M. Rage gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India. Eye 2007; 21: 395-401.
60. Kumaramanickavel G, Ramprasad VL, Sripriya S, Upadyay NK, Paul PG, Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. J Diabetes Complications 2002; 16: 391-394.
61. Liu L, Xiang K. RAGE Gly82Ser polymorphism in diabetic microangiopathy. Diabetes Care 1999; 22: 646.
62. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001; 50: 1505-1511.
63. JiXiong X, BiLin X, MingGong Y, ShuQin L. -429 T/C and -374 T/A polymorphisms of RAGE gene promoter are not associated with diabetic retinopathy in Chinese patients with type 2 diabetes. Diabetes Care 2003; 26: 2696-2697.
64. Globocnik Petrovic M, Steblovnik K, Peterlin B, Petrovic D. The - 429 T/C and -374 T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes. Klin Monbl Augenheilkd 2003; 220: 873-876.
65. Kang P, Tian C, Jia C. Association of RAGE gene polymorphisms with type 2 diabetes mellitus, diabetic retinopathy and diabetic nephropathy. Gene 2012; 500: 1-9.
66. Wagner J, Jan Danser AH, Derkx FH, et al. Demonstration of rennin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996; 80: 159-163.
67. Thomas GN, Critchley JA, Tomlinson B, et al. Renin-angiotensin system gene polymorphisms and retinopathy in Chinese patients with type 2 diabetes. Diabetes Care 2003; 26: 1643-1644.
68. Matsumoto A, Iwashima Y, Abiko A, et al. Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy. Diabetes Res Clin Pract 2000; 50: 195-202.
69. Feghhi M, Nikzamir A, Esteghamati A, Farahi F, Nakhjavani M, Rashidi A. The relationship between angiotensin-converting enzyme insertion/deletion polymorphism and proliferative retinopathy in type 2 diabetes. Diabetes Res Clin Pract 2008; 81: e1-e4.
70. Gutierrez C, Vendrell J, Pastor R, et al. Angiotensin I-converting enzyme and angiotensinogen gene polymorphisms in non-insulindependent diabetes mellitus: lack of relationship with diabetic nephropathy and retinopathy in a Caucasian Mediterranean population. Metabolism 1997; 46: 976-980.
71. Cruickshanks KJ, Vadheim CM, Moss SE, et al. Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 yr of age. Diabetes 1992; 41: 879-885.
72. Wong TY, Cruickshanks KJ, Klein R, et al. HLA-DR3 and DR4 and their relation to the incidence and progression of diabetic retinopathy. Ophthalmology 2002; 109: 275-281.
73. Larkins RG, Martin FI, Tait BD. HLA patterns and diabetic retinopathy. Br Med J 1978; 1: 1111.
74. Barbosa J, Ramsay RC, Knobloch WH, Cantrill HL, Noreen H, King R, Yunis E. Histocompatibility antigen frequencies in diabetic retinopathy. Am J Ophthalmol 1980; 90: 148-153.
75. Dornan TL, Ting A, McPherson CK, et al. Genetic susceptibility to the development of retinopathy in insulin-dependent diabetics. Diabetes 1982; 31: 226-231.
76. Malone JI, Grizzard S, Espinoza LR, Achenbach KE, Van Cader TC. Risk factors for retinopathy in youth. Pediatrics 1984; 73: 756-761.
77. Baker RS, Rand LI, Krolewski AS, Maki T, Warram JH, Aiello LM. Influence of HLA-DR phenotype and myopia on the risk of nonproliferative and proliferative diabetic retinopathy. Am J Ophthalmol 1986; 102: 693-700.
78. Steck AK, Rewers MJ. Genetics of type 1 diabetes. Clin Chem 2011; 57: 176-85.
79. Aribi M. Candidate genes implicated in type 1 diabetes susceptibility. Curr Diabetes Rev 2008; 4: 110-121.
80. Carroll MC, Katzman P, Alicot EM, et al. Linkage map of the human major histocompatibility complex including tumor necrosis factor genes. Proc Natl Acad Sci USA 1987; 84: 8535-8539.
81. Hawrami K, Hitman GA, Rema M, et al. An association in noninsulin- dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism. Hum Immunol 1996; 46: 49-54.
82. Kumaramanickavel G, Sripriya S, Vellanki RN, et al. Tumor necrosis factor alleleic polymorphism with diabetic retinopathy in India. Diabetes Res Clin Pract 2001; 54: 89-94.
83. Sobrin L, Green T, Sim X, et al. Family Investigation of Nephropathy and Diabetes-Eye Research Group, Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate Gene Association Resource (CARe). Invest Ophthalmol Vis Sci 2011; 52: 7593-7602.
84. Warpeha KM, Xu W, Liu L, et al. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy. FASEB J 1999; 13: 1825-1832.
85. Kumaramanickavel G, Sripriya S, Vellanki RN, et al. Inducible nitric oxide synthase gene and diabetic retinopathy in Asian India patients. Clin Genet 2002; 61: 344-348.
86. Matsubara Y, Murata M, Maruyama T, et al. Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen. Blood 2000; 95: 1560-1564.
87. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care 1997; 20: 1304-1309.
88. Santos A, Salguero ML, Gurrola C, Munoz F, Roig-Melo E, Panduro A. The epsilon4 allele of apolipoprotein E gene is a potential risk factor for the severity of macular edema in type 2 diabetic Mexican patients. Ophthalmic Genet 2002; 23: 13-19.
89. Maeda M, Yamamoto I, Fukuda M, et al. MTHFR gene polymorphism is susceptible to diabetic retinopathy but not to diabetic nephropathy in Japanese type 2 diabetic patients. J Diabetes Complications 2008; 22: 119-125.
90. Syreeni A, El-Osta A, Forsblom C, et al. FinnDiane Study Group. Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. Diabetes 2011; 60: 3073-3080.
91. Uthra S, Raman R, Mukesh BN, et al. Diabetic retinopathy and IGF-1 gene polymorphic cytosine-adenine repeats in a Southern Indian cohort. Ophthalmic Res 2007; 39: 294-9.
92. Uthra S, Raman R, Mukesh BN, et al. Protein kinase C beta (PRKCB1) and pigment epithelium derived factor (PEDF) gene polymorphisms and diabetic retinopathy in a south Indian cohort. Ophthalmic Genet 2010; 31: 18-23.
93. Vinita K, Sripriya S, Prathiba K, et al. SNDREAMS Project. ICAM-1 K469E polymorphism is a genetic determinant for the clinical risk factors of T2D subjects with retinopathy in Indians; a population-based case-control study. BMJ Open 2012; 2: pii: e001036.
94. Melzer D, Murray A, Hurst AJ, et al. Effects of the diabetes linked TCF7L2 polymorphism in a representative older population. BMC Med 2006; 4: 34.
95. Buchbinder S, Rudofsky G Jr, Humpert PM, et al. The DG10S478 variant in the TCF7L2 gene is not associated with microvascular complications in type 2 diabetes. Exp Clin Endocrinol Diabetes 2008; 116: 211-214.
96. Malecki MT, Cyganek K, Mirkiewicz-Sieradzka B, et al. Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes. Diabetes Res Clin Pract 2008; 80: 139-145.
97. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E, Berlin Diabetes Mellits (BeDiaM) Study. Peroxisome proliferatoractivated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 2002; 51: 2653-2657.
98. Stefanski A, Majkowska L, Ciechanowicz A, et al. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res 2006; 37: 736-743.
99. Uthra S, Raman R, Mukesh BN, et al. Intron 4 VNTR of endothelial nitric oxide synthase (eNOS) gene and diabetic retinopathy in type 2 patients in southern India. Ophthalmic Genet 2007; 28: 77-81.
100. Liu ZH, Guan TJ, Chen ZH, Li LS. Glucose transporter (GLUT1) allele (Xbal-) associated with nephropathy in non-insulindependent diabetes mellitus. Kidney Int 1999; 55: 1843-1848.
101. Lambrinoudaki I, Vlachou SA, Creatsas G. Genetics in gestational diabetes mellitus: association with incidence, severity, pregnancy outcome and reponse to treatment. Curr Diabetes Rev 2010; 6: 393-399.
102. Klein R, Klein BE, Moss SE. The relationship of systemic hypertension to changes in the retinal vasculature: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 1997; 95: 329-348.
103. Cugati S, Cikamatana L, Wang JJ, Kifley A, Liew G, Mitchell P. Five-year incidence and progression of vascular retinopathy in persons without diabetes: the Blue Mountains Eye Study. Eye 2006; 20: 1239-1245.
104. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med 2010; 27: 249-256.
105. Javey G, Schwartz SG, Flynn HW Jr. Emerging pharmacotherapies for diabetic macular edema. Exp Diabetes Res 2012; 2012: 548732.
106. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
107. Schwartz SG, Brantley MA Jr. Pharmacogenetics and age-related macular degeneration. J Ophthalmol 2011; 2011: 252549.